Board of Directors

Lars holds a MSc in Business Administration. Former Senior Advisor within healthcare at Bain Capital. Senior management positions in pharma and medtech companies including Agilent, Dako, Applied Biosystems Inc. and Medtronic Europe Sarl. Board member in the Lundbeck Foundation, H Lundbeck A/S, ALK-Abelló A/S, Tecan AG, BPL Plc-UK and Vitrolife AB.

Holdings: 410 630 B-shares, 50 000 warrants 2019/2023 (TO4)

Ulf is a board-certified oncologist trained at the Karolinska Institute. In more than 20 years of experience in pharmaceutical drug development, he has been Vice President of Clinical Research and Development, Oncology, at Celgene Inc., and has held similar positions at Pfizer, Eli Lilly, and Takeda Pharmaceuticals in the US. He has had important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta®, and Revlimid®. In addition, his work has been pivotal in several multibillion-dollar acquisitions, such as Celgene’s acquisitions of Abraxis and Pharmion.

Holdings: 25 000 warrants 2019/2023 (TO4)

Maria has 30 years of experience in the life science and diagnostic industry and she has previously held senior management positions as CEO, business area manager and marketing manager at international diagnostic companies such as Pharmacia Diagnostics, Boehringer Mannheim, Roche Scandinavia, Phadia and Thermo Fisher. She has extensive experience of successfully introducing novel diagnostic products globally. Maria is currently CEO of Prolight Diagnostics.

Holdings: 9 750 B-shares, 25 000 warrants 2019/2023 (TO4)

Henrik is the CEO of Primas Invest AB, which has a portfolio of investments in Life Science. He has experience as an entrepreneur and CEO in the distribution and retail area and has successfully built up a larger international business.

Holdings: 424,106 B-shares

Jesper received an MSc in Engineering Physics from the Swedish Royal Institute of Technology and a PhD from the Royal Institute of Technology and CERN. Jesper is CEO of Arcoma AB. He was formerly Vice President of Elekta’s Neuroscience division and General Manager, Mammography, at Philips Healthcare and the CEO of Sectra Mamea, AB, from 2004 until it was acquired by Philips in 2011. In these positions, he managed the microdose mammography business, taking it from a start-up to an international medical technology company. Jesper has also held management positions at Huber+Suhner and at Allgon.

Holdings: 41 085 A-shares, 38 200 B-shares, 25 000 warrants 2019/2023 (TO4)

Anders Rylander has an MSc in Mechanical Engineering with specialties in Industrial Economics and Management from the Swedish Royal Institute of Technology. He has been a management consultant for more than 15 years, at companies such as Accenture and Andersen Consulting. Anders co-founded Axholmen, a management consulting firm that focuses on improving the operational efficiency of large corporations in the Nordic market. He also founded Arinvest, a private equity investment firm investing in the clean-tech and life science business areas.

Holdings: 3 575 640 A-shares, 368 956 B-shares